What are the recommended dosing regimens and treatment durations for fosfomycin in uncomplicated cystitis and in complicated urinary tract infections, including adjustments for renal impairment?

Fosfomycin Dosing and Duration

For uncomplicated cystitis in women, fosfomycin trometamol 3 grams as a single oral dose is the recommended regimen, though it has slightly inferior efficacy compared to other first-line agents. 1, 2

Uncomplicated Cystitis

Standard Dosing:

• Fosfomycin trometamol 3 grams orally as a single dose 1, 3, 4, 2
• Can be taken with or without food 2
• Must be mixed with water before ingestion—never take in dry form 2

Clinical Context: The IDSA/ESCMID guidelines position fosfomycin as an appropriate first-line choice due to minimal resistance and low collateral damage (minimal disruption of normal flora), but acknowledge it appears to have inferior efficacy compared to standard short-course regimens like nitrofurantoin (5 days) or trimethoprim-sulfamethoxazole (3 days) 1. The 2021 American College of Physicians guidelines similarly recommend fosfomycin as a single dose option alongside nitrofurantoin (5 days) and TMP-SMZ (3 days) 3.

The microbiological cure rate with single-dose fosfomycin is approximately 78-80%, compared to 86-92% with nitrofurantoin 1. Clinical cure rates are 90-91% 1. The 2024 EAU guidelines list fosfomycin 3g single dose as first-line treatment specifically for women with uncomplicated cystitis 4.

Complicated Urinary Tract Infections

For complicated UTIs, the evidence is limited but emerging data supports multi-dose regimens:

Multi-dose Oral Regimen (Off-label):

• Fosfomycin 3 grams orally every 48-72 hours for 3 total doses (most common regimen studied) 5, 6, 7
• This translates to dosing on days 1,3, and 5 (every 48 hours) or days 1,4, and 7 (every 72 hours)

Clinical Evidence: A Chinese multicenter study of 361 patients with complicated lower UTI using three doses (days 1,3,5) showed clinical efficacy of 62.69% for complicated UTI, 77.22% for recurrent UTI, and 94.71% for acute uncomplicated cystitis 5. A retrospective U.S. study of 171 treatment episodes showed clinical resolution in 67.3% and bacteriologic resolution in 48.7% 6.

Important Caveat: Multi-dose oral fosfomycin for complicated UTI should be reserved for patients who:

• Have failed other first-line agents
• Are infected with multidrug-resistant organisms
• Cannot tolerate standard therapies due to adverse effects or allergies 7

Intravenous Fosfomycin (where available):

• 6 grams IV every 8 hours for 7 days (14 days if concurrent bacteremia) 7
• The ZEUS trial demonstrated IV fosfomycin was noninferior to piperacillin-tazobactam for complicated upper UTI and acute pyelonephritis, with superior outcomes specifically for complicated upper UTI and against ESBL-producing and carbapenem-resistant organisms 7

Multidrug-Resistant Organisms

For uncomplicated UTI due to VRE or CRE:

• Single dose fosfomycin 3 grams orally is recommended 8
• This represents an important niche for fosfomycin given its activity against multidrug-resistant Enterobacterales, including ESBL-producing and carbapenem-resistant E. coli 9, 7

Renal Impairment Adjustments

No dosage adjustment is required for renal impairment 2. However, understand the pharmacokinetic implications:

• In patients with renal impairment (CrCl 7-54 mL/min), the half-life increases from 11 to 50 hours 2
• Urinary recovery decreases from 32% to 11% with severe renal impairment 2
• In anuric patients on hemodialysis, the half-life extends to 40 hours 2
• Despite reduced urinary excretion, therapeutic urinary concentrations are still achieved 2

Clinical Implication: While no formal dose adjustment is recommended by the FDA label, the significantly prolonged half-life and reduced urinary excretion in severe renal impairment may affect efficacy for UTI treatment, though therapeutic urinary levels are maintained.

Special Populations

Elderly Patients:

• No dosage adjustment necessary 2
• No differences in urinary excretion observed 2

Pregnancy:

• Fosfomycin crosses the placental barrier 2
• Considered safe with favorable profile in pregnancy 9

Pharmacokinetic Considerations

After a single 3-gram oral dose:

• Peak urine concentration: ~706 mcg/mL at 2-4 hours (fasting) 2
• Urinary concentrations remain >100 mcg/mL for 48 hours 2, 9
• Bioavailability: 30-38% (reduced with food but total urinary excretion unchanged) 2
• Half-life: 5.7 hours 2

Drug Interaction: Metoclopramide lowers serum concentrations and urinary excretion of fosfomycin—avoid concurrent use 2

Pyelonephritis

Fosfomycin is NOT recommended for acute pyelonephritis 1. The IDSA/ESCMID guidelines do not include fosfomycin in treatment recommendations for pyelonephritis, recommending instead fluoroquinolones (5-7 days) or TMP-SMZ (14 days) 1, 3. Insufficient data exists for oral fosfomycin in pyelonephritis 10, 7.